DEFENCE THERAPEUTICS INC
Commented by Nico Popp on April 27th, 2022 | 11:54 CEST
Where the sentiment is right: BioNTech, Defence Therapeutics, Amazon
If you want to sell air mattresses in November, you will not succeed even with huge discounts. It is a similar story when selecting stocks. In order to reap returns, investors need to assess the market and bet on the stocks that will be in demand in the near future. In the case of vaccine stocks, the air seemed to be out recently. But now, there are growing indications that more vaccine doses may be needed. We take a look at the sentiment of three stocks.
Read
Commented by Stefan Feulner on April 19th, 2022 | 12:10 CEST
Bayer, Defence Therapeutics, Formycon - Biotech stocks facing transformation
The pharmaceutical industry proved to be a key industry in the Corona pandemic, developing tests, vaccines and drugs at record speed and making them available in large quantities. In the process, biotechnology emerged as the innovative engine. The development of new compounds is particularly important for the pharmaceutical industry, as patent protection for many blockbuster drugs will expire in the future or has already expired. For this reason, the pharmaceutical industry is now entering biotechs much more frequently in the early development phases of a new drug. As a result, early-stage development companies already offer opportunities for multiplication.
Read
Commented by André Will-Laudien on April 1st, 2022 | 12:43 CEST
BioNTech, Defence Therapeutics, Valneva, CureVac - Stocks with blockbuster potential!
With the Ukraine crisis, international vaccination activity has taken a back seat. The world's northern hemisphere is gearing up for next summer, so flu diseases are also slowly taking a back seat. However, the COVID virus will likely continue to mutate over the summer and will reappear in a new guise in the fall. Germany's maximum vaccination rate of 76% has been reached, with just under a quarter of the population ultimately foregoing vaccination after lengthy public measures. For the major biotech companies, it is now a case of - The country needs new products! There are still many areas of application in the field of mRNA. Which stocks stand out with their pipeline?
Read
Commented by Nico Popp on March 22nd, 2022 | 11:22 CET
In the right place at the right time: BioNTech, Defence Therapeutics, Bayer
For years, the pandemic has kept the world on tenterhooks. Currently, the epidemic is taking a break, at least in the media. But while the world is looking tautly at Ukraine and more and more refugees are arriving in Germany, the Omicron figures are rising once more. In some cases, the incidence in Germany is over 3,000. Although fewer and fewer people are dying, more people than ever are in quarantine. We look at BioNTech, a typical pandemic stock, and present other exciting investments from the healthcare sector.
Read
Commented by Carsten Mainitz on March 14th, 2022 | 12:47 CET
BioNTech, Defence Therapeutics, MorphoSys - Shares with blockbuster potential!
Developing a blockbuster drug is the highest achievement in the pharmaceutical industry. A blockbuster is defined as a drug that can generate more than USD 1 billion in revenues per year. According to experts, the vaccine Comirnaty, developed by BioNTech and Pfizer, is likely to have brought in sales of well over USD 30 billion, thus clearly breaking the blockbuster barrier. Outside of vaccine research, there are also numerous companies with high long-term potential.
Read
Commented by Armin Schulz on March 7th, 2022 | 13:05 CET
Valneva, Defence Therapeutics, MorphoSys - Blockbuster potential
Every pharmaceutical or biotech company wants a blockbuster. This term refers to a drug that generates annual sales of at least USD 1 billion. The best-known blockbuster drug currently is the Corona vaccine from BioNTech. In 2020, the rheumatism drug Humira was in the top spot with sales of over USD 20 billion. The Mainz-based vaccine manufacturer is likely to have significantly surpassed this mark in 2021. If a company hits the big time, it can reap the rewards for 20 years before the patent expires. Today, we take a look at three companies that have potential blockbusters.
Read
Commented by Stefan Feulner on March 4th, 2022 | 13:33 CET
Bayer, Defence Therapeutics, Merck KGaA - At the start of the trend
The biotech industry is the innovative engine for a pharmaceutical industry dependent on new concepts due to the shift from blockbuster products to personalized medicine. Even before Corona, more than EUR seven billion per year was invested in R&D in 2019. The development of new drugs is particularly important for the pharmaceutical industry, as patent protection for many blockbuster drugs is expiring or has already expired. For this reason, the pharmaceutical industry is now much more often entering biotech companies in the early development phases of a new drug. The example of vaccine manufacturers has successfully highlighted this strategy, which will also be applied to other diseases in the future.
Read
Commented by André Will-Laudien on February 9th, 2022 | 12:22 CET
MorphoSys, Defence Therapeutics, Valneva, CureVac - Find the bio blockbuster!
The biotech sector is a highly dynamic growth market within the equity universe. It is characterized by investment volumes of unprecedented size, which is also the reason for the high innovation rate characteristic of the sector. Price reactions to positive or negative surprises can be very volatile, and these tendencies are often exacerbated by the intervention of stop orders or the occurrence of derivative slippage. Vaccine manufacturers were down over 50% across the board, as the pandemic is being traded as a phase-out. The vaccination rate does not appear to be increasing significantly. Where are the opportunities for investors at the moment?
Read
Commented by Armin Schulz on January 31st, 2022 | 13:31 CET
BioNTech, Defence Therapeutics, Mainz Biomed - After Corona, cancer is the next hype
The euphoria surrounding vaccine manufacturers has come to an end. The majority of investors believe that the end of the pandemic is near with Omicron. More and more states are abandoning restrictions and slowly returning to normalcy. If that happens, one of the biggest hypes of the last decade will come to an end. The pharmaceutical and biotech industries have earned very well from it. After the hype is before the hype. The next big story is cancer, and there are more and more cancer cases, so fighting the disease is a lucrative business. A lot is happening in this area, so we are looking at three companies today.
Read
Commented by Nico Popp on January 25th, 2022 | 10:15 CET
BioNTech, Defence Therapeutics, Nordex: Investors must pay attention here!
"Defying cancer" was the headline of the Frankfurter Allgemeine Zeitung a few days ago. The interview was illustrated with the two leading BioNTech heads, Özlem Türeci and Uğur Şahin. The famous German scientists' statement revolved around further projects for BioNTech and the fight against cancer. At the same time, BioNTech's stock, like many other pandemic winners, dropped. What does this mean for investors now?
Read